发明名称 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
摘要 A method is provided for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1 selected from the group including neuropathies of the optic nerve and of the olfactory nerve, neuralgia of the trigmeninal nerve, Bell's paralysis, amyotrophic lateral sclerosis, osteoporosis, anthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs clinical syndromes of reduced height, cachexia and acute or chronic hepatic necrosis, Turner's syndrome, sarcopoenia, growth hormone insensitivity syndromes, obesity, asthenia, myasthenia and heart asthenia, immunodeficiences and reperfusion injuries, and for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration, cutaneous, intestinal and hepatic tissue regeneration and the formation of dentine, that includes administering, to a patient in need thereof, at least one selected from the group including L-acetylcarnitine, L-isovalerylcarnitine, and L-propionylcarnitine or pharmacologically acceptable salts thereof. The present invention also relates to a method and composition for treating HCV and/or increasing the levels of IGF-1 of a patient in need thereof, the composition including at least one selected from the group including L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine and pharmacologically acceptable salts thereof and mixtures thereof; and at least one selected from the group including L-carnitine, coenzyme Q10, vitamin E and Se-L-methionine and pharmaceutically acceptable salts and derivatives thereof and mixtures thereof.
申请公布号 US6380252(B1) 申请公布日期 2002.04.30
申请号 US20000510669 申请日期 2000.02.22
申请人 SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.;MENDES S.R.L. 发明人 DE SIMONE CLAUDIO
分类号 A61K31/221;(IPC1-7):A61K31/205 主分类号 A61K31/221
代理机构 代理人
主权项
地址